One-tube test could expand cervical cancer screening, speed diagnosis

LSU LCMC Health research team granted $1.2M to address barriers to cervical cancer prevention

A research team from Louisiana State University LCMC Health Cancer Center has been awarded a $1.5 million grant to eliminate barriers from cervical cancer prevention.

January 26, 2024

Vol.50 No.04

Drugs & Targets

FDA approves Keytruda + chemoradiotherapy for FIGO 2014 stage 3-4A cervical cancer

FDA approved Keytruda (pembrolizumab) with chemoradiotherapy for patients with FIGO 2014 stage 3-4A cervical cancer.

January 19, 2024

Vol.50 No.03

Drugs & Targets

FDA grants Merck sBLA priority review for Keytruda + chemoradiotherapy in cervical cancer

FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for Keytruda (pembrolizumab) in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) as treatment with definitive intent for newly diagnosed patients with high-risk, locally advanced cervical cancer.

September 22, 2023

Vol.49 No.35

As U.S. courts, politicians take aim at preventive care, cervical cancer screening declines, HPV vaccine uptake stays uneven

In an era of intensifying judicial repudiation of evidence-based guidelines and deepening public mistrust toward science, America’s screening rate for cervical cancer has been declining.

July 21, 2023

Vol.49 No.29

By Matthew Bin Han Ong

Conversation with The Cancer Letter

St. Jude’s Heather Brandt: NCI cancer centers must leverage community trust to boost HPV vaccine uptake in children

St. Jude’s Path to a Bright Future, an HPV awareness and vaccination campaign with nearly 160 partners, is aimed at reducing that disease burden by targeting children in a crucial age range.

July 21, 2023

Vol.49 No.29

By Matthew Bin Han Ong

Conversation with The Cancer Letter

NCI’s Douglas Lowy: HPV vaccination is important, but it’s even more important to get screened

The standard of care in HPV vaccination may soon change if a one-dose regimen is found to be just as efficacious as two or three doses—once a large trial that NCI is conducting in Costa Rica, in young women ages 12 to 16, is ready to report final results in a few years. “We’ve done...

July 21, 2023

Vol.49 No.29

By Matthew Bin Han Ong

One-tube test could expand cervical cancer screening, speed diagnosis

YOU MAY BE INTERESTED IN

LSU LCMC Health research team granted $1.2M to address barriers to cervical cancer prevention

FDA approves Keytruda + chemoradiotherapy for FIGO 2014 stage 3-4A cervical cancer

FDA grants Merck sBLA priority review for Keytruda + chemoradiotherapy in cervical cancer

As U.S. courts, politicians take aim at preventive care, cervical cancer screening declines, HPV vaccine uptake stays uneven

St. Jude’s Heather Brandt: NCI cancer centers must leverage community trust to boost HPV vaccine uptake in children

NCI’s Douglas Lowy: HPV vaccination is important, but it’s even more important to get screened

Renew today!

Subscriber content

Login